Compare TKLF & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | LEXX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Japan | Canada |
| Employees | N/A | 7 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.5M |
| IPO Year | 2020 | 2011 |
| Metric | TKLF | LEXX |
|---|---|---|
| Price | $1.60 | $4.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.6K | ★ 48.5K |
| Earning Date | 12-18-2026 | 11-27-2026 |
| Dividend Yield | ★ 17.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,915.00 |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $1.30 | $0.35 |
| 52 Week High | $3.49 | $21.60 |
| Indicator | TKLF | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 61.49 |
| Support Level | $1.30 | $2.67 |
| Resistance Level | $1.64 | $10.26 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 40.89 | 90.67 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.